-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Oscar Health, Raises Price Target to $36

Benzinga·10/12/2026 21:12:27
Listen to the news
UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $26 to $36.